Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Xcovery Holding Company
Scientific Title
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients